Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the primary progressive subtype of MS. Clinical success has increased interest in the role of B cells in the patho...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-01-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2020.595547/full |
| _version_ | 1818600255776620544 |
|---|---|
| author | Charles A. Roach Anne H. Cross |
| author_facet | Charles A. Roach Anne H. Cross |
| author_sort | Charles A. Roach |
| collection | DOAJ |
| description | Several clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the primary progressive subtype of MS. Clinical success has increased interest in the role of B cells in the pathogenesis of MS and in ways to potentially improve upon current B cell therapies. In this mini review, we will critically review previous and ongoing clinical trials of anti-CD20 monoclonal antibodies in MS, including rituximab, ocrelizumab, ofatumumab, and ublituximab. Side effects and adverse event profiles will be discussed. Studies examining the proposed mechanisms of action of B cell depleting therapies will also be reviewed. |
| first_indexed | 2024-12-16T12:32:35Z |
| format | Article |
| id | doaj.art-e77edd1a5f434cbaa4754432679c6f01 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-12-16T12:32:35Z |
| publishDate | 2021-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-e77edd1a5f434cbaa4754432679c6f012022-12-21T22:31:40ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-01-011110.3389/fneur.2020.595547595547Anti-CD20 B Cell Treatment for Relapsing Multiple SclerosisCharles A. RoachAnne H. CrossSeveral clinical trials have demonstrated the efficacy of lytic therapies targeting B cells in the treatment of relapsing multiple sclerosis (MS). More modest efficacy has been noted in the primary progressive subtype of MS. Clinical success has increased interest in the role of B cells in the pathogenesis of MS and in ways to potentially improve upon current B cell therapies. In this mini review, we will critically review previous and ongoing clinical trials of anti-CD20 monoclonal antibodies in MS, including rituximab, ocrelizumab, ofatumumab, and ublituximab. Side effects and adverse event profiles will be discussed. Studies examining the proposed mechanisms of action of B cell depleting therapies will also be reviewed.https://www.frontiersin.org/articles/10.3389/fneur.2020.595547/fullmultiple sclerosisanti-CD20 agentrituximabofatumumabocrelizumabublituximab |
| spellingShingle | Charles A. Roach Anne H. Cross Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis Frontiers in Neurology multiple sclerosis anti-CD20 agent rituximab ofatumumab ocrelizumab ublituximab |
| title | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis |
| title_full | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis |
| title_fullStr | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis |
| title_full_unstemmed | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis |
| title_short | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis |
| title_sort | anti cd20 b cell treatment for relapsing multiple sclerosis |
| topic | multiple sclerosis anti-CD20 agent rituximab ofatumumab ocrelizumab ublituximab |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2020.595547/full |
| work_keys_str_mv | AT charlesaroach anticd20bcelltreatmentforrelapsingmultiplesclerosis AT annehcross anticd20bcelltreatmentforrelapsingmultiplesclerosis |